Literature DB >> 31549186

[Periodic fever and pancytopenia in a 35-year-old patient].

M Schmutz1, T Schaller2, B Kubuschok3, C Fleischmann4, K Hirschbühl3, S Dintner2, T Häckel5, B Märkl2, M Trepel3, R Claus3.   

Abstract

MEDICAL HISTORY AND INITIAL
PRESENTATION: A 35-year-old patient with a previous history of persistent episodic fever, sore throat, myalgia, and cephalgia presented for evaluation of pancytopenia. He had no recent travel history, except for a stay in Italy 1 year prior to admission and in Spain several years in the past. DIAGNOSTIC WORKUP: Laboratory evaluation confirmed pancytopenia, agranulocytosis, and elevated infection parameters without indicative serological results en par with lymphadenitis colli. Computed tomography scanning revealed cervical lymphadenopathy, hepatosplenomegaly, and colitis with occult perforation of the sigmoid colon. Bone marrow biopsy showed an infiltration of polyclonal plasma cells. Lymph node biopsy was compatible with necrotizing lymphadenitis. DIAGNOSIS: Polymerase chain reaction analysis of a lymph node specimen confirmed the presence of Leishmania species, thereby enabling the diagnosis of visceral Leishmania. THERAPY COURSE: Treatment with liposomal amphotericin B was initiated. Both fever and lymphadenopathy quickly resolved.
CONCLUSION: VL is a clinically pleiotropic, severe disease with fatal outcome if left untreated. It often presents with distinct similarities to hematologic malignancies. Exacerbation can occasionally occur as fulminant macrophage activation syndrome. Disease incidence is globally increasing and has not peaked as yet. A complex interplay between pathogen and the immune system is the key pathophysiological mechanism.

Entities:  

Keywords:  Amphotericin B, liposomal; Fever of unknown origin; Hypergammaglobulinemia; Leishmaniasis; Splenomegaly

Mesh:

Substances:

Year:  2019        PMID: 31549186     DOI: 10.1007/s00108-019-00679-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  10 in total

Review 1.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

2.  IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis.

Authors:  Shalini Gautam; Rajiv Kumar; Radheshyam Maurya; Susanne Nylén; Nasim Ansari; Madhukar Rai; Shyam Sundar; David Sacks
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

Review 3.  The regulation of IL-10 production by immune cells.

Authors:  Margarida Saraiva; Anne O'Garra
Journal:  Nat Rev Immunol       Date:  2010-02-15       Impact factor: 53.106

4.  A summary of the evidence for the change in European distribution of phlebotomine sand flies (Diptera: Psychodidae) of public health importance.

Authors:  Jolyon M Medlock; Kayleigh M Hansford; Wim Van Bortel; Herve Zeller; Bulent Alten
Journal:  J Vector Ecol       Date:  2014-06       Impact factor: 1.671

Review 5.  Comparative study of rK39 Leishmania antigen for serodiagnosis of visceral leishmaniasis: systematic review with meta-analysis.

Authors:  Zuinara Maia; Monique Lírio; Sóstenes Mistro; Carlos Maurício Cardeal Mendes; Sanjay R Mehta; Roberto Badaro
Journal:  PLoS Negl Trop Dis       Date:  2012-01-31

Review 6.  Immune regulation during chronic visceral leishmaniasis.

Authors:  Rebecca J Faleiro; Rajiv Kumar; Louise M Hafner; Christian R Engwerda
Journal:  PLoS Negl Trop Dis       Date:  2014-07-10

7.  Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).

Authors:  Naomi Aronson; Barbara L Herwaldt; Michael Libman; Richard Pearson; Rogelio Lopez-Velez; Peter Weina; Edgar Carvalho; Moshe Ephros; Selma Jeronimo; Alan Magill
Journal:  Am J Trop Med Hyg       Date:  2016-12-07       Impact factor: 2.345

Review 8.  Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment.

Authors:  Sarah P Georgiadou; Konstantinos P Makaritsis; George N Dalekos
Journal:  J Transl Int Med       Date:  2015-06-30

Review 9.  Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Authors:  Wim Adriaensen; Thomas P C Dorlo; Guido Vanham; Luc Kestens; Paul M Kaye; Johan van Griensven
Journal:  Front Immunol       Date:  2018-01-12       Impact factor: 7.561

Review 10.  New insights into leishmaniasis in the immunosuppressed.

Authors:  Hannah Akuffo; Carlos Costa; Johan van Griensven; Sakib Burza; Javier Moreno; Mercè Herrero
Journal:  PLoS Negl Trop Dis       Date:  2018-05-10
  10 in total
  1 in total

Review 1.  Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021-A Comprehensive Review.

Authors:  Rafael Rocha; André Pereira; Carla Maia
Journal:  Pathogens       Date:  2022-08-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.